Publications
and Scientific Papers
Introduction
Lipid nanoparticles (LNPs) are the mainstream delivery vehicles for nucleic acid-based vaccines and therapeutics, such as the COVID-19 mRNA vaccines. Providence Therapeutics Holdings Inc. Has developed the INTENT™ LNP reagents for optimized delivery of nucleic acids. INTENT™ LNP reagents were rationally designed on chemistry principles, and selected by traits such as transfection efficiency, low toxicity, and target specificity for in vitro and in vivo payload delivery. Here, we present the data on one of the INTENT™ LNP reagents. Compared to a commercially available transfection reagent, the INTENT™-3 LNP reagent was highly efficient at transfecting mRNA into cell lines in vitro, and hard-to-transfect human primary cells such as dendritic cells and macrophages ex vivo, with low toxicity. In vivo, the INTENT™-3 LNP reagent efficiently transfected dendritic cells and macrophages and delivered mRNA vaccines to elicit robust immune response in mice. Furthermore, the INTENT™-3 LNP reagent can be simply mixed with mRNA and incubated for 5 minutes at room temperature to form a self-assembling LNP for transfection without needing special equipment or additional steps. Taken together, these results demonstrate that the INTENT™-3 LNP reagents can efficiently transfect dendritic cells and macrophages, highlighting its potential as a promising delivery vehicle for nucleic acids in vaccines and cell therapies.